Encephalopathy - Pipeline Review, H1 2018

Encephalopathy - Pipeline Review, H1 2018


  • Products Id :- GMDHC10499IDB
  • |
  • Pages: 78
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Encephalopathy-Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy-Pipeline Review, H1 2018, provides an overview of the Encephalopathy (Central Nervous System) pipeline landscape.

Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching and muscle weakness. Causes include traumas or injuries, genetic, liver disease, hypoxic condition, Lyme disease and organ failure.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalopathy-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Encephalopathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalopathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Encephalopathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalopathy (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Encephalopathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Encephalopathy (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Encephalopathy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Encephalopathy (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Encephalopathy (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Encephalopathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Encephalopathy-Overview

Encephalopathy-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Encephalopathy-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Encephalopathy-Companies Involved in Therapeutics Development

Celgene Corp

Chiesi Farmaceutici SpA

GW Pharmaceuticals Plc

JS Genetics Inc

Knopp Biosciences LLC

Marinus Pharmaceuticals Inc

Mithra Pharmaceuticals SA

Pairnomix LLC

ProThera Biologics Inc

SciFluor Life Sciences LLC

Takeda Pharmaceutical Co Ltd

Zynerba Pharmaceuticals Inc

Encephalopathy-Drug Profiles

Alda-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diazoxide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Estetrol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ganaxolone-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GWP-42003-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melatonin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proteins for Hypoxic-Ischemic Brain Injury-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-0034-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Kv7.2 for Central Nervous System Disorders and Tinnitus-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block KCNQ2 for Epileptic Encephalopathy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block SCN8A for Epileptic Encephalopathy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Encephalopathy and Periventricular Leukomalacia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Hematological Malignancies, Hypoxic-ischemic Encephalopathy and Solid Tumor-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-935-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRP-601-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Encephalopathy-Dormant Projects

Encephalopathy-Product Development Milestones

Featured News & Press Releases

Apr 10, 2018: Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE)

Jan 03, 2018: Zynerba Pharmaceuticals Provides Update on cannabidiol

Jun 09, 2017: Mithra Receives Orphan Drug Designation From EMA For E4 In Neonatal Encephalopathy

Aug 06, 2015: GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy

Apr 24, 2015: GW Pharmaceuticals Receives Orphan Drug Designation From FDA for Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Encephalopathy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

List of Tables

Number of Products under Development for Encephalopathy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Encephalopathy-Pipeline by Celgene Corp, H1 2018

Encephalopathy-Pipeline by Chiesi Farmaceutici SpA, H1 2018

Encephalopathy-Pipeline by GW Pharmaceuticals Plc, H1 2018

Encephalopathy-Pipeline by JS Genetics Inc, H1 2018

Encephalopathy-Pipeline by Knopp Biosciences LLC, H1 2018

Encephalopathy-Pipeline by Marinus Pharmaceuticals Inc, H1 2018

Encephalopathy-Pipeline by Mithra Pharmaceuticals SA, H1 2018

Encephalopathy-Pipeline by Pairnomix LLC, H1 2018

Encephalopathy-Pipeline by ProThera Biologics Inc, H1 2018

Encephalopathy-Pipeline by SciFluor Life Sciences LLC, H1 2018

Encephalopathy-Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Encephalopathy-Pipeline by Zynerba Pharmaceuticals Inc, H1 2018

Encephalopathy-Dormant Projects, H1 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Celgene Corp

Chiesi Farmaceutici SpA

GW Pharmaceuticals Plc

JS Genetics Inc

Knopp Biosciences LLC

Marinus Pharmaceuticals Inc

Mithra Pharmaceuticals SA

Pairnomix LLC

ProThera Biologics Inc

SciFluor Life Sciences LLC

Takeda Pharmaceutical Co Ltd

Zynerba Pharmaceuticals Inc

Encephalopathy Therapeutic Products under Development, Key Players in Encephalopathy Therapeutics, Encephalopathy Pipeline Overview, Encephalopathy Pipeline, Encephalopathy Pipeline Assessment

select a license
Single User License
USD 2000 INR 142680
Site License
USD 4000 INR 285360
Corporate User License
USD 6000 INR 428040

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com